Merck (MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, becoming ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware: Rahway, New Jersey Wednesday, April 30, 2025, 09:00 Hrs [IST] Merck, known as MSD out ...

Merck (NYSE:MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, ...

Merck has launched construction of a $1 billion biologics facility in Wilmington, set to become the U.S. production hub for ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

The company expects labs at the new facility to be fully operational by 2028 and produce experimental drugs by 2030 ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Keytruda在2024年为 默沙东 创造近300亿美元收入，已成为癌症治疗的基石和制药史上最畅销产品。 但这款占 默沙东 近半数营收的药物，预计将在2028年 ...